A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease

This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe. The efficacy and safety of the drug was tested for twice daily dosing against once daily dosing.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease
• Intervention / Treatment: Drug: NVA237; Drug: Salbutamol; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 776
• Phase: Phase 4

Contacts and Locations

Study Locations

• Belgium
  • Limburg
    • Genk, Limburg, Belgium, 3600
      • Novartis Investigative Site
  • Namur
    • Jambes, Namur, Belgium, 5100
      • Novartis Investigative Site
• Bulgaria
  • Gabrovo, Bulgaria, 5300
    • Novartis Investigative Site
  • Kozloduj, Bulgaria, 3320
    • Novartis Investigative Site
  • Lom, Bulgaria, 3600
    • Novartis Investigative Site
  • Lovech, Bulgaria, 5500
    • Novartis Investigative Site
  • Montana, Bulgaria, 3400
    • Novartis Investigative Site
  • Razgrad, Bulgaria, 7200
    • Novartis Investigative Site
  • Roman, Bulgaria, 3130
    • Novartis Investigative Site
  • Ruse, Bulgaria, 7000
    • Novartis Investigative Site
  • Silistra, Bulgaria, 7500
    • Novartis Investigative Site
  • Sliven, Bulgaria, 8800
    • Novartis Investigative Site
  • Smolyan, Bulgaria, 4700
    • Novartis Investigative Site
  • Sofia, Bulgaria, 1431
    • Novartis Investigative Site
  • Sofia, Bulgaria, 1202
    • Novartis Investigative Site
  • Sofia, Bulgaria, 1233
    • Novartis Investigative Site
  • Troyan, Bulgaria, 5600
    • Novartis Investigative Site
  • Veliko Tarnovo, Bulgaria, 5000
    • Novartis Investigative Site
  • Vidin, Bulgaria, 3700
    • Novartis Investigative Site
  • Gabrovo
    • Sevlievo, Gabrovo, Bulgaria, 5400
      • Novartis Investigative Site
  • Sofia-Grad
    • Sofia, Sofia-Grad, Bulgaria, 1336
      • Novartis Investigative Site
• Finland
  • Turku, Finland, FIN-20100
    • Novartis Investigative Site
• Germany
  • Berlin, Germany, 10117
    • Novartis Investigative Site
  • Dresden, Germany, 01069
    • Novartis Investigative Site
  • Frankfurt, Germany, 60596
    • Novartis Investigative Site
  • Greifswald, Germany, 17475
    • Novartis Investigative Site
  • Lubeck, Germany, 23552
    • Novartis Investigative Site
  • Schwerin, Germany, 19055
    • Novartis Investigative Site
  • Wiesbaden, Germany, 65187
    • Novartis Investigative Site
  • Baden-Württemberg
    • Heidelberg, Baden-Württemberg, Germany, 69126
      • Novartis Investigative Site
  • Niedersachsen
    • Hannover, Niedersachsen, Germany, 30159
      • Novartis Investigative Site
    • Hannover, Niedersachsen, Germany, 30167
      • Novartis Investigative Site
  • Rheinland-Pfalz
    • Koblenz, Rheinland-Pfalz, Germany, 56068
      • Novartis Investigative Site
  • Schleswig-Holstein
    • Großhansdorf, Schleswig-Holstein, Germany, 22927
      • Novartis Investigative Site
• Hungary
  • Balassagyarmat, Hungary, 2660
    • Novartis Investigative Site
  • Debrecen, Hungary, 4032
    • Novartis Investigative Site
  • Farkasgyepu, Hungary, 8582
    • Novartis Investigative Site
  • Pecs, Hungary, 7635
    • Novartis Investigative Site
  • Sopron, Hungary, H-9400
    • Novartis Investigative Site
  • Szarvas, Hungary, 5540
    • Novartis Investigative Site
  • Szeged, Hungary, 6722
    • Novartis Investigative Site
• Israel
  • Rehovot, Israel, 7610001
    • Novartis Investigative Site
• Poland
  • Bialystok, Poland, 15-044
    • Novartis Investigative Site
  • Gdansk, Poland, 80 952
    • Novartis Investigative Site
  • Kielce, Poland, 25-751
    • Novartis Investigative Site
  • Lodz, Poland, 90-141
    • Novartis Investigative Site
  • Sopot, Poland, 81-741
    • Novartis Investigative Site
  • Wilkowice, Poland, 43-365
    • Novartis Investigative Site
  • Dolnoslaskie
    • Wroclaw, Dolnoslaskie, Poland, 53-301
      • Novartis Investigative Site
  • Lódzkie
    • Lodz, Lódzkie, Poland, 90-153
      • Novartis Investigative Site
  • Malopolskie
    • Tarnow, Malopolskie, Poland, 33-100
      • Novartis Investigative Site
  • Slaskie
    • Chorzow, Slaskie, Poland, 41-500
      • Novartis Investigative Site
• Romania
  • Baia Mare, Romania
    • Novartis Investigative Site
  • Bucharest, Romania, 030317
    • Novartis Investigative Site
  • Bucuresti, Romania, 050159
    • Novartis Investigative Site
  • Cluj Napoca, Romania, 400162
    • Novartis Investigative Site
  • Cluj-Napoca, Romania, 400371
    • Novartis Investigative Site
  • Dolj
    • Craiova, Dolj, Romania, 200515
      • Novartis Investigative Site
  • Jud. Constanta
    • Constanta, Jud. Constanta, Romania, 900002
      • Novartis Investigative Site
  • Mures
    • Tg Mures, Mures, Romania, 540136
      • Novartis Investigative Site
  • Timis
    • Timisoara, Timis, Romania, 300310
      • Novartis Investigative Site
• Russian Federation
  • Chelyabinsk, Russian Federation, 454021
    • Novartis Investigative Site
  • Izhevsk, Russian Federation, 426061
    • Novartis Investigative Site
  • Kemerovo, Russian Federation, 650002
    • Novartis Investigative Site
  • Kemerovo, Russian Federation, 650099
    • Novartis Investigative Site
  • N.Novgorod, Russian Federation, 603126
    • Novartis Investigative Site
  • Nizhny Novgorod, Russian Federation, 603011
    • Novartis Investigative Site
  • Ryazan, Russian Federation, 390039
    • Novartis Investigative Site
  • Sestroretsk, Russian Federation, 197706
    • Novartis Investigative Site
  • Smolensk, Russian Federation, 214019
    • Novartis Investigative Site
  • St Petersburg, Russian Federation, 194325
    • Novartis Investigative Site
  • St. Petersburg, Russian Federation, 197022
    • Novartis Investigative Site
  • Yaroslavl, Russian Federation, 150003
    • Novartis Investigative Site
  • Yaroslavl, Russian Federation, 150062
    • Novartis Investigative Site
  • Yaroslavl, Russian Federation, 150000
    • Novartis Investigative Site
  • Tatarstan Republic
    • Kazan, Tatarstan Republic, Russian Federation, 420015
      • Novartis Investigative Site
• Sweden
  • Lund, Sweden, SE-221 85
    • Novartis Investigative Site
  • Ostergotlands Lan
    • Linkoping, Ostergotlands Lan, Sweden, 587 58
      • Novartis Investigative Site
  • Skane Lan
    • Malmo, Skane Lan, Sweden, 21152
      • Novartis Investigative Site
  • Sodermanlands Lan
    • Lidingo, Sodermanlands Lan, Sweden, 18158
      • Novartis Investigative Site
  • Vastra Gotalands Lan
    • Göteborg, Vastra Gotalands Lan, Sweden, SE-413 45
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 41 years to 84 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Written informed consent must be obtained before any assessment is performed
• Male and female adults aged ≥40 years
• Patients with stable COPD according to the current GOLD strategy (GOLD 2014)
• Current or ex-smokers who have a smoking history of at least 10 pack years- an ex-smoker may be defined as a subject who has not smoked for ≥ 6 months at screening
• mMRC grade of at least 2 at Visit 101
• Patients with airflow limitation indicated by a post-bronchodilator FEV1 ≥ 30 % and < 80 % of the predicted normal, and a post-bronchodilator FEV1/FVC < 0.70 at Visit 101.

Exclusion Criteria:

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test; Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment
• Patients with Type I or uncontrolled Type II diabetes; Patients with a history of long QT syndrome or whose QTc measured at run-in (Fridericia method) is prolonged (>450 ms for males and >460 for females) and confirmed by a central assessor
• Patients requiring long term oxygen therapy prescribed for >12 h per day; Patients with any history of asthma.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NVA237 Twice daily; Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.	Drug: NVA237; NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1; Other Names: glycopyrronioum bromide; Drug: Salbutamol; All patients received salbutamol (100 μg) as only rescue medication
Experimental: NVA237 Once daily; Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.	Drug: NVA237; NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1; Other Names: glycopyrronioum bromide; Drug: Salbutamol; All patients received salbutamol (100 μg) as only rescue medication; Drug: Placebo; Placebo to NVA237

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12	Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1 at Week 12. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.	Baseline, Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 12	The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 12 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.	Baseline, 0-12 hour, 0-24 hour , 12-24 hour post dose at Week 12
Change From Baseline in Area Under The Curve (AUC 0-12 Hour) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at Day 1	The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for 0-12 hour, post dosing at Day 1 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.	Baseline, 0-12 hour post dose at Day 1
Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 26	The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 26 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.	Baseline, 0-12 hour, 0-24 hour , 12-24 hour post dose at Week 26
Change From Baseline in Total St. George's Respiratory Questionnaire (SGRQ) Score at Week 12 and Week 26	The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity; Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness; Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. Higher values corresponded to greater impairment of health status.	Baseline, 12 Weeks, 26 Weeks
Percentage of Patients With a Clinically Significant Improvement in St George Respiratory Questionnaire at Week 12 and Week 26	The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity; Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness; Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. A clinically significant improvement is defined as ≥ 4 unit improvement from baseline score (a decrease of ≥ 4).	Baseline, 12 Weeks, 26 Weeks
Change From Baseline in Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26	Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score.	Baseline, 12 Weeks, 26 Weeks
Percentage of Patients With a Clinically Important Improvement on Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26	Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. Clinically important improvement indicates ≥ 1 unit in the TDI focal score at Weeks 12 and 26 in comparison to BDI focal score (an increase of ≥ 1).	Baseline, 12 Weeks, 26 Weeks
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 26	Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.	Baseline, Day 1, Week 26
Change From Baseline in Forced Vital Capacity (FVC) at Individual Timepoints at Week 26	Mixed model for repeated measures was used to analyze change from baseline in FVC. Baseline FVC is defined as the average of the -45 min and -15 min FVC values taken on Day 1 prior to first dose.	Baseline, Week 26 (Day 183-184)
Change From Baseline in Inspiratory Capacity (IC) at Individual Timepoints at Week 26	Mixed model for repeated measures was used to analyze change from baseline in IC.	Baseline, Week 26 (Day 183-184)
Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Individual Timepoints at Week 26	Mixed model for repeated measures was used to analyze change from baseline in FEV1. Baseline FEV1 is defined as the average of the -45 min and -15 min FEV1 values taken on Day 1 prior to first dose.	Baseline, Week 26 (Day 183-184)
Change From Baseline in the Percentage of Days With no Rescue Medication Use Over the 26 Weeks	Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. change from baseline in percentage of days without rescue medication usage over 26 weeks was analyzed.	Baseline, 26 Weeks
Change From Baseline in Mean Daily COPD Symptom Score at Week 26	Patients reported symptoms by using an electronic diary. The mean daily total symptom score, the mean morning symptom score and the mean evening symptom score were calculated for each patient over 26 weeks. Each symptom measured in a numeric rating scale of 0-10; 0 indicates no symptom and 10 indicates severe symptom. 0 is no waking due to symptoms, 1 woke up once, 2 woke up more than once due to symptoms ; 10 was the worst score.The daily score for an individual symptom score was the worst of the morning and evening scores on a particular day. If either the morning or evening score was missing for a symptom then the non-missing value was taken as the worst. A negative change indicates improvement. Only the scores for the 6 COPD symptoms (respiratory symptoms, cough, wheeze, production of sputum, sputum color, and breathlessness) were used to derive the total symptom score	Baseline, 26 Weeks
Number of Patients With Adverse Events, Serious Adverse Events and Death	This endpoint reports patients affected by any adverse events (AE), serious adverse events (SAE) and death. Only treatment emergent AE, SAE, deaths are reported for this endpoint.	26 Weeks

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): June 24, 2015
• Primary Completion (Actual): November 16, 2016
• Study Completion (Actual): November 16, 2016

Study Registration Dates

• First Submitted: February 19, 2015
• First Submitted That Met QC Criteria: February 19, 2015
• First Posted (Estimate): February 25, 2015

Study Record Updates

• Last Update Posted (Actual): August 9, 2019
• Last Update Submitted That Met QC Criteria: June 21, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Keywords: Respiratory Tract Diseases; Lung Diseases, Obstructive; COPD; Antimuscarinic; Chronic Obstructive Pulmonary Disease; Lung Disease; Pulmonary Disease, Chronic Obstructive; Lung Function; LAMA; Anticholinergic; Chronic Obstructive Airway Disease; Chronic Obstructive Lung Disease; Muscarinic receptor antagonist
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Adrenergic Agonists; Adjuvants, Anesthesia; Anticonvulsants; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Reproductive Control Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Tocolytic Agents; Albuterol; Glycopyrrolate; Bromides
• Other Study ID Numbers: CNVA237A2320